Ritholtz Wealth Management Sells 1,564 Shares of Eli Lilly and Company (NYSE:LLY)

Ritholtz Wealth Management reduced its position in Eli Lilly and Company (NYSE:LLY) by 6.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 23,082 shares of the company’s stock after selling 1,564 shares during the period. Eli Lilly and Company accounts for about 0.5% of Ritholtz Wealth Management’s portfolio, making the stock its 28th largest position. Ritholtz Wealth Management’s holdings in Eli Lilly and Company were worth $13,455,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. JGP Wealth Management LLC boosted its stake in Eli Lilly and Company by 0.9% in the 4th quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock worth $1,074,000 after purchasing an additional 16 shares in the last quarter. Cassia Capital Partners LLC boosted its stake in Eli Lilly and Company by 1.8% in the 3rd quarter. Cassia Capital Partners LLC now owns 951 shares of the company’s stock worth $511,000 after purchasing an additional 17 shares in the last quarter. Walkner Condon Financial Advisors LLC boosted its stake in Eli Lilly and Company by 2.8% in the 3rd quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company’s stock worth $334,000 after purchasing an additional 17 shares in the last quarter. Patton Albertson Miller Group LLC boosted its stake in Eli Lilly and Company by 2.8% in the 3rd quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock worth $335,000 after purchasing an additional 17 shares in the last quarter. Finally, Valley Wealth Managers Inc. boosted its stake in Eli Lilly and Company by 1.3% in the 3rd quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock worth $688,000 after purchasing an additional 17 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Performance

LLY opened at $777.96 on Friday. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The firm has a fifty day moving average price of $730.97 and a 200 day moving average price of $637.01. Eli Lilly and Company has a 1 year low of $334.58 and a 1 year high of $800.78. The stock has a market cap of $739.19 billion, a P/E ratio of 134.13, a P/E/G ratio of 1.71 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same period in the prior year, the business posted $2.09 earnings per share. Equities research analysts anticipate that Eli Lilly and Company will post 12.42 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on LLY shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, February 20th. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Barclays upped their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. BMO Capital Markets upped their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. Finally, Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $689.52.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 34,538 shares of the company’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $631.81, for a total transaction of $21,821,453.78. Following the completion of the transaction, the insider now directly owns 99,719,884 shares in the company, valued at $63,004,019,910.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders sold 195,055 shares of company stock worth $125,254,657. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.